Skip to main content
TipRanks
Go Ultimate75% OFF

RegenXBio (RGNX) Revenue by Segment

1,133 Followers

Revenue by Segment

Analyzes income from different business units, highlighting which segments drive growth and profitability, and indicating potential areas for strategic focus or improvement.

-$25.00M$0.00$25.00M$50.00M$75.00M$100.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

Revenue is lumpy and milestone-driven: steady Zolgensma royalties historically provided a recurring base but collapsed in early‑2026, while licensing receipts (a large Nippon Shinyaku payment in 2025 and the $100M AbbVie milestone recognized in Q2‑2026) create outsized spikes. Management’s call confirms the AbbVie milestone; investors should treat near-term revenue as milestone-dependent and focus on sustainability of royalties, timing of future milestones, and regulatory risk that could delay expected cashflow from upcoming approvals.

RGNX Revenue by Segment

DateZolgensma RoyaltiesOther License and RoyaltyNippon Shinyaku Licenses
Sep 30, 2026$5.24M$0.00$0.00
Jun 30, 2026$3.84M$100.00M$0.00
Mar 31, 2026$5.05M$38.00K$0.00
Dec 31, 2025$24.18M-$2.09M$204.00K
Sep 30, 2025$23.59M$19.00K$0.00
Jun 30, 2025$18.42M$216.00K$2.72M
Mar 31, 2025$16.99M$2.04M$69.98M
Dec 31, 2024$20.66M$558.00K$0.00
Sep 30, 2024$23.87M$325.00K$0.00
Jun 30, 2024$21.76M$532.00K$0.00
Mar 31, 2024$15.21M$408.00K$0.00
Dec 31, 2023$21.86M$348.00K$0.00
Sep 30, 2023$28.36M$550.00K$0.00
Jun 30, 2023$18.96M$1.01M$0.00
Mar 31, 2023$16.13M$3.01M$0.00
Dec 31, 2022$26.79M$4.56M$0.00
Sep 30, 2022$25.20M$1.31M$0.00
Jun 30, 2022$28.39M$4.26M$0.00
Mar 31, 2022$21.54M$679.00K$0.00
Dec 31, 2021$28.03M$622.00K$0.00
Sep 30, 2021$30.25M$519.00K$0.00
Jun 30, 2021$18.43M$3.61M$0.00
Mar 31, 2021$18.26M$621.00K$0.00